Interpretation of lipoprotein-associated phospholipase A2 levels is influenced by cardiac disease, comorbidities, extension of atherosclerosis and treatments
Authors:
- 24 October 2012
- journal article
- Published by Elsevier in International Journal of Cardiology
- Vol. 168 (1) , 132-138
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Association of Lipoprotein-Associated Phospholipase A2 with Coronary Artery Disease in African-Americans and CaucasiansThe Journal of Clinical Endocrinology & Metabolism, 2010
- Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studiesThe Lancet, 2010
- Lipoprotein-Associated Phospholipase A 2 and Risk of Congestive Heart Failure in Older AdultsCirculation: Heart Failure, 2009
- Plasma lipoprotein-associated phospholipase A2 levels in heart failure: Association with mortality in the communityAtherosclerosis, 2008
- Lipoprotein-Associated Phospholipase A2 and Risk of StrokeThe American Journal of Cardiology, 2008
- Identifying the Vulnerable Patient with Rupture-Prone PlaqueThe American Journal of Cardiology, 2008
- Inflammatory Activation During Coronary Artery Surgery and Its Dose-Dependent Modulation by Statin/ACE-Inhibitor CombinationArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Lipoprotein-Associated Phospholipase A2 and Measures of Extracoronary AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Effects of Atorvastatin Versus Other Statins on Fasting and Postprandial C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Patients With Coronary Heart Disease Versus Control SubjectsThe American Journal of Cardiology, 2005
- Inflammation and Matrix Metalloproteinases in the Enlarging Abdominal Aortic AneurysmArteriosclerosis, Thrombosis, and Vascular Biology, 1995